logo

For the Inventor, By the Inventor

Tokyo, Japan

Nobuaki Shindo

This inventor holds 12 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Astellas Pharma Gmbh, Curegene K.k., Lion Corporation. Active years: 1990-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobuaki Shindo. Retrieved from https://idiyas.com/inventor/nobuaki-shindo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 83.3

 

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 75(Granted Patents)


Location History:

  • Ibaraki, JP (2003 - 2006)
  • Tsukuba, JP (2006)
  • Tokyo, JP (1990 - 2018)

Company Filing History:

goldMedal9 out of 424 
 
Astellas Pharma Gmbh
 patents
silverMedal6 out of 6 
 
Curegene K.k.
 patents
bronzeMedal2 out of 271 
 
Lion Corporation
 patents
4. 1 out of 329 
 
Yamanouchi Pharmaceutical Company Ltd.
 patents
where one patent can have more than one assignee

Years Active: 1990-2018

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 9932589 - EML4-ALK fusion gene (2018-04-03),
2. 9029521 - EML4-ALK fusion gene (2015-05-12),
3. 8318702 - Di(arylamino)aryl compounds (2012-11-27),
4. 8197818 - EML4-ALK fusion gene (2012-06-12),
5. 7964710 - EML4-ALK fusion gene (2011-06-21),
6. 7728120 - EML4-ALK fusion gene (2010-06-01),
7. 7605131 - EML4-ALK fusion gene (2009-10-20),
8. 7098186 - Depsipeptide compound (2006-08-29),
9. 7098024 - Depsipeptide compound (2006-08-29),
10. 6670326 - Depsipeptide compound (2003-12-30),
11. 5261537 - Container (1993-11-16),
12. 4976369 - Container (1990-12-11),

Title: Innovator Spotlight: Nobuaki Shindo Revolutionizing Cancer Research

Introduction:

Nobuaki Shindo, a prominent inventor based in Tokyo, Japan, has made significant contributions to the field of oncology with his groundbreaking research and patented innovations.

Latest Patents:

Among his 12 patents, one of Nobuaki Shindo's notable inventions is the EML4-ALK fusion gene. This discovery identified a fusion gene present in certain cancer patients as an oncogene, leading to the development of novel diagnostic and therapeutic methods for cancer treatment.

Career Highlights:

With a background in molecular biology and genetics, Nobuaki Shindo has worked diligently to advance the understanding of cancer biology. He has held key positions at renowned companies such as Astellas Pharma GmbH and Curegene K.K., where he has spearheaded innovative research projects.

Collaborations:

Throughout his career, Nobuaki Shindo has collaborated with esteemed professionals in the field of oncology. Notable coworkers include Hiroyuki Mano and Sadao Kuromitsu, who have worked alongside him on various research initiatives aimed at improving cancer diagnosis and treatment.

Conclusion:

Nobuaki Shindo's relentless dedication to cancer research and innovation has not only earned him recognition within the scientific community but has also paved the way for new and improved strategies in the fight against cancer. His pioneering work continues to inspire future generations of inventors and researchers in the quest for improved cancer care and outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…